2024 SV Therapeutics Impact & ESG ReportRead More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 18 May 2021Portfolio NewsMestag Therapeutics announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease
- 17 May 2021Portfolio NewsImbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope , at the American College of Cardiology 70th Annual Scientific Session & Expo
- 12 May 2021Portfolio NewsXilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium
- 10 May 2021Portfolio NewsTherini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
- 5 May 2021Portfolio NewsXilio Therapeutics Appoints Christina Rossi to its Board of Directors
- 26 April 2021Portfolio NewsCatamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer
- 20 April 2021Portfolio NewsMestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer
- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 24 February 2021Portfolio NewsXilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors